It seems that the mucoadhesive nanoparticles can increase paclitaxel transport by opening tight junctions and bypassing the efflux pump of P-gp.
It seems that the mucoadhesive nanoparticles can increase paclitaxel transport by opening tight junctions and bypassing the efflux pump of P-glycoprotein.
An open-label multicenter phase II study of paclitaxel in patients with RA was completed in July 2008, although results of this are still pending [ 58].
This study was a single-center, prospective, open-label, randomized phase II study of paclitaxel and carboplatin with intercalated gefitinib (PCG) or PC alone (PC) for advanced NSCLC in a selected population of smokers with wild-type EGFR.
Open image in new window Figure 5 EB1 increases the ability of paclitaxel to stabilize microtubules and stimulates paclitaxel binding to microtubules.
Patients treated on the open-label phase of the protocol received 80 mg/m2 paclitaxel per week for a total of 12 weeks.
Open image in new window Figure 2 expressionsincreasesases paclitaxel sensitivity in breast cancer cell lines.
DTX, in particular, is broadly indicated for the treatment of non-small cell lung cancer, and breast, prostate, stomach and head and neck cancers [ 29], though these results remain open to debate [ 30], and is clinically preferred to paclitaxel [ 29].
Open image in new window Figure 4 enhancesnces the activity of paclitaxel to stimulate microtubule assembly.
Open image in new window Figure 3 EB1 promotes the activity of paclitaxel to induce mitotic arrest and apoptosis.
In a separate open-label, randomized study, addition of platinum to trastuzumab and paclitaxel improved PFS and ORR but not OS (Robert et al, 2006).
